<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cancer Research UK Cambridge Institute</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/315ACF59-92D1-4302-9C0C-3CAAEB7D3601"><gtr:id>315ACF59-92D1-4302-9C0C-3CAAEB7D3601</gtr:id><gtr:firstName>Ioannis</gtr:firstName><gtr:surname>Gounaris</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001957"><gtr:id>7C46CD7E-BE1E-41B4-97CB-D1B4E919A236</gtr:id><gtr:title>Role of ARID1A in endometrial proliferation, endometriosis and endometriosis-associated ovarian cancer pathogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1001957</gtr:grantReference><gtr:abstractText>Ovarian cancer is one of the leading causes of death from cancer in women. There are 4 major types of ovarian cancer. The clear-cell and endometrioid types of ovarian cancer are related to a condition called endometriosis. The latter is a common cause of pelvic pain and infertility. Clear-cell cancer in particular, is very difficult to treat when it has spread because currently available chemotherapies are not effective. Recent research has identified a gene, called ARID1A, which appears to play a role in these two types of ovarian cancer. Specifically, mutations of this gene are found in approximately a third of endometrioid cancers and a half of clear cell cancers as well as in endometriosis. This research project aims to find out how mutations in ARID1A cause cancer. This will involve testing the effects of the mutation on growth and hormonal control in cells cultured in a petri dish. It will also involve experiments in mice that have this gene mutation. If we are able to understand better how this mutation causes cancer, then we will be able to design better treatments that will allow these patients to live longer or have less symptoms.</gtr:abstractText><gtr:technicalSummary>Ovarian cancer is the leading cause of death from gynaecologic malignancies in the western world. Together, endometrioid and clear-cell ovarian adenocarcinomas account for approximately 20% of ovarian cancer and are epidemiologically related to endometriosis. Very recent work has identified mutations in ARID1A, a component of the SWI/SNF chromatin remodelling complex, in 57% of ovarian clear-cell adenocarcinomas (OCCA). Importantly, in 2 examined cases of OCCA, adjacent foci of atypical endometriosis carried the same ARID1A mutation, implying that ARID1A mutations are an early driver event in carcinogenesis. Previous work has shown that ARID1A plays a role in the maintenance of an embryonic stem-cell phenotype, cell differentiation, cell cycle arrest and steroid-hormone mediated gene transactivation.
The first aim of this project is to study the role of ARID1A in the control of oestrogen and progesterone regulation of normal endometrium and endometriotic lesions. This will involve in vitro assays of proliferation in disaggregated and explanted endometrial tissue from ARID1Aflox mice as well as in vivo experimentation following site-specific inactivation of ARID1A in the same mouse model. To identify the transcriptional targets of ARID1A, microarray and ChIP-Seq experiments are planned.
The second aim of the project is to create a mouse model of OCCA that will reflect the association between endometriosis and OCCA observed in humans. For this, ARID1A will be knocked down or out on a background of endometriosis mouse models.
Current medical treatments for OCCA are unsatisfactory. In particular, and in stark contrast to the more common high grade serous ovarian cancers, these tumours are resistant to standard platinum-based chemotherapy. An improved understanding of the molecular and cellular events that result from ARID1A mutation has the potential to identify novel treatment targets for this difficult to treat malignancy. The parallel development of a mouse model of OCCA will provide the opportunity and possibility for preclinical testing of therapeutics.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>255206</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CRI Open Day May 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>35FEFC49-C452-4E0D-803F-60F1FB62CAC4</gtr:id><gtr:impact>200 CRUK supporters and donors visited the Institute and were briefed on various groups' research projects

Positive feedback from the visitors with regards to their awareness of current research projects carried out at the CRI</gtr:impact><gtr:outcomeId>F5iRDK2D3oG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Early Career Award</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2650B50D-A5C6-4225-88D4-52B0405595D2</gtr:id><gtr:outcomeId>Wiu1uypC1FS</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>89E1ECC3-F0FE-473D-9DC9-AE9BBF8B4A62</gtr:id><gtr:title>Effect of hypoxia, glucose deprivation and glycogen phosphorylase inhibition on ovarian clear cell cancer cell line proliferation.</gtr:title><gtr:parentPublicationTitle>ESMO38/ECC2013</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f3355471f32cf7a8d8ea93a2de3333"><gtr:id>66f3355471f32cf7a8d8ea93a2de3333</gtr:id><gtr:otherNames>Gounaris I</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>GBcD9aLEwDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF525C9D-C717-4F62-B1F8-0FCF113DAE72</gtr:id><gtr:title>Molecular pathogenesis of ovarian clear cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f3355471f32cf7a8d8ea93a2de3333"><gtr:id>66f3355471f32cf7a8d8ea93a2de3333</gtr:id><gtr:otherNames>Gounaris I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>5675e3fa45ac2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>493FFD87-9B88-40B8-B65F-18CFC7B5D001</gtr:id><gtr:title>Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f3355471f32cf7a8d8ea93a2de3333"><gtr:id>66f3355471f32cf7a8d8ea93a2de3333</gtr:id><gtr:otherNames>Gounaris I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_13508_28_21898874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C94FDAA8-5D48-4B29-A4F7-5AA4F2329F21</gtr:id><gtr:title>PYGL and GYS1 are novel therapeutic targets in ovarian clear cell carcinoma (OCCC)</gtr:title><gtr:parentPublicationTitle>2013 NCRI Cancer Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f3355471f32cf7a8d8ea93a2de3333"><gtr:id>66f3355471f32cf7a8d8ea93a2de3333</gtr:id><gtr:otherNames>Gounaris I</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>Jod8bn8iPP2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>460CC973-0B4A-4E0F-8479-D4FDD2BA908D</gtr:id><gtr:title>ARID1A role in cell cycle regulation and proliferation in mouse and human gynaecological tissues reveals potential therapeutic targets.</gtr:title><gtr:parentPublicationTitle>Annals of Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f3355471f32cf7a8d8ea93a2de3333"><gtr:id>66f3355471f32cf7a8d8ea93a2de3333</gtr:id><gtr:otherNames>Gounaris I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457de06beedc6.25975477</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001957</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>